Which has preferable valuation & earnings, BWAY or PDEX?

Pro-Dex has higher revenue and earnings than Brainsway. Pro-Dex is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainsway $52.22M 11.57 $7.57M $0.35 43.03 Pro-Dex $66.59M 3.01 $8.98M $3.62 17.37

Is BWAY or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to Brainsway's net margin of 15.68%. Pro-Dex's return on equity of 22.78% beat Brainsway's return on equity. Company Net Margins Return on Equity Return on Assets Brainsway 15.68% 12.28% 7.75% Pro-Dex 16.08% 22.78% 14.30%

Which has better valuation and earnings, CLPT or PDEX?

Pro-Dex has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ClearPoint Neuro $36.97M 14.20 -$25.54M -$1.01 N/A Pro-Dex $66.59M 3.01 $8.98M $3.62 17.37

Is CLPT or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to ClearPoint Neuro's net margin of -71.57%. Pro-Dex's return on equity of 22.78% beat ClearPoint Neuro's return on equity. Company Net Margins Return on Equity Return on Assets ClearPoint Neuro -71.57% -140.96% -36.98% Pro-Dex 16.08% 22.78% 14.30%

Pro-Dex (PDEX) Competitors

$62.89 +0.85 (+1.37%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$62.85 -0.04 (-0.06%)

As of 07/10/2026 04:13 PM Eastern

Compare

PDEX vs. SGP, SSII, TCMD, BWAY, and CLPT

Should you buy Pro-Dex stock or one of its competitors? MarketBeat compares Pro-Dex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pro-Dex include Spyglass Pharma (SGP), SS Innovations International (SSII), Tactile Systems Technology (TCMD), Brainsway (BWAY), and ClearPoint Neuro (CLPT). These companies are all part of the "medical equipment" industry.

How does Pro-Dex compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

In the previous week, Spyglass Pharma had 2 more articles in the media than Pro-Dex. MarketBeat recorded 3 mentions for Spyglass Pharma and 1 mentions for Pro-Dex. Spyglass Pharma's average media sentiment score of 0.47 beat Pro-Dex's score of 0.00 indicating that Spyglass Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Spyglass Pharma	Neutral
Pro-Dex	Neutral

Pro-Dex has higher revenue and earnings than Spyglass Pharma. Spyglass Pharma is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A
Pro-Dex	$66.59M	3.01	$8.98M	$3.62	17.37

15.3% of Pro-Dex shares are owned by institutional investors. 45.9% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Pro-Dex has a net margin of 16.08% compared to Spyglass Pharma's net margin of 0.00%. Pro-Dex's return on equity of 22.78% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
Pro-Dex	16.08%	22.78%	14.30%

Spyglass Pharma currently has a consensus price target of $45.00, indicating a potential upside of 99.82%. Pro-Dex has a consensus price target of $70.00, indicating a potential upside of 11.31%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Spyglass Pharma is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Pro-Dex beats Spyglass Pharma on 8 of the 13 factors compared between the two stocks.

How does Pro-Dex compare to SS Innovations International?

Pro-Dex (NASDAQ:PDEX) and SS Innovations International (NASDAQ:SSII) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Pro-Dex has a net margin of 16.08% compared to SS Innovations International's net margin of -20.69%. Pro-Dex's return on equity of 22.78% beat SS Innovations International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	16.08%	22.78%	14.30%
SS Innovations International	-20.69%	-23.00%	-13.18%

Pro-Dex has higher revenue and earnings than SS Innovations International. SS Innovations International is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$66.59M	3.01	$8.98M	$3.62	17.37
SS Innovations International	$42.49M	17.85	-$12.13M	-$0.05	N/A

Pro-Dex has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market. Comparatively, SS Innovations International has a beta of -1.96, indicating that its share price is 296% less volatile than the broader market.

Pro-Dex currently has a consensus target price of $70.00, suggesting a potential upside of 11.31%. SS Innovations International has a consensus target price of $7.00, suggesting a potential upside of 84.70%. Given SS Innovations International's higher possible upside, analysts clearly believe SS Innovations International is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, SS Innovations International had 8 more articles in the media than Pro-Dex. MarketBeat recorded 9 mentions for SS Innovations International and 1 mentions for Pro-Dex. SS Innovations International's average media sentiment score of 0.41 beat Pro-Dex's score of 0.00 indicating that SS Innovations International is being referred to more favorably in the news media.

Company	Overall Sentiment
Pro-Dex	Neutral
SS Innovations International	Neutral

15.3% of Pro-Dex shares are owned by institutional investors. 45.9% of Pro-Dex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Pro-Dex beats SS Innovations International on 12 of the 16 factors compared between the two stocks.

How does Pro-Dex compare to Tactile Systems Technology?

Tactile Systems Technology (NASDAQ:TCMD) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Tactile Systems Technology currently has a consensus price target of $38.60, indicating a potential upside of 29.40%. Pro-Dex has a consensus price target of $70.00, indicating a potential upside of 11.31%. Given Tactile Systems Technology's stronger consensus rating and higher possible upside, research analysts clearly believe Tactile Systems Technology is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Tactile Systems Technology and Tactile Systems Technology both had 1 articles in the media. Tactile Systems Technology's average media sentiment score of 0.00 equaled Pro-Dex'saverage media sentiment score.

Company	Overall Sentiment
Tactile Systems Technology	Neutral
Pro-Dex	Neutral

83.4% of Tactile Systems Technology shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 2.1% of Tactile Systems Technology shares are owned by company insiders. Comparatively, 45.9% of Pro-Dex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tactile Systems Technology has higher revenue and earnings than Pro-Dex. Pro-Dex is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tactile Systems Technology	$329.52M	2.04	$19.09M	$0.88	33.90
Pro-Dex	$66.59M	3.01	$8.98M	$3.62	17.37

Tactile Systems Technology has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

Pro-Dex has a net margin of 16.08% compared to Tactile Systems Technology's net margin of 5.91%. Pro-Dex's return on equity of 22.78% beat Tactile Systems Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tactile Systems Technology	5.91%	9.70%	7.53%
Pro-Dex	16.08%	22.78%	14.30%

Summary

Tactile Systems Technology beats Pro-Dex on 9 of the 15 factors compared between the two stocks.

How does Pro-Dex compare to Brainsway?

Brainsway (NASDAQ:BWAY) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Brainsway currently has a consensus target price of $16.00, suggesting a potential upside of 6.24%. Pro-Dex has a consensus target price of $70.00, suggesting a potential upside of 11.31%. Given Pro-Dex's higher possible upside, analysts plainly believe Pro-Dex is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Brainsway had 1 more articles in the media than Pro-Dex. MarketBeat recorded 2 mentions for Brainsway and 1 mentions for Pro-Dex. Brainsway's average media sentiment score of 0.00 equaled Pro-Dex'saverage media sentiment score.

Company	Overall Sentiment
Brainsway	Neutral
Pro-Dex	Neutral

Pro-Dex has higher revenue and earnings than Brainsway. Pro-Dex is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.22M	11.57	$7.57M	$0.35	43.03
Pro-Dex	$66.59M	3.01	$8.98M	$3.62	17.37

Brainsway has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market.

Pro-Dex has a net margin of 16.08% compared to Brainsway's net margin of 15.68%. Pro-Dex's return on equity of 22.78% beat Brainsway's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.68%	12.28%	7.75%
Pro-Dex	16.08%	22.78%	14.30%

30.1% of Brainsway shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 19.0% of Brainsway shares are owned by company insiders. Comparatively, 45.9% of Pro-Dex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Pro-Dex beats Brainsway on 8 of the 15 factors compared between the two stocks.

How does Pro-Dex compare to ClearPoint Neuro?

ClearPoint Neuro (NASDAQ:CLPT) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Pro-Dex has a net margin of 16.08% compared to ClearPoint Neuro's net margin of -71.57%. Pro-Dex's return on equity of 22.78% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-71.57%	-140.96%	-36.98%
Pro-Dex	16.08%	22.78%	14.30%

In the previous week, ClearPoint Neuro and ClearPoint Neuro both had 1 articles in the media. ClearPoint Neuro's average media sentiment score of 0.67 beat Pro-Dex's score of 0.00 indicating that ClearPoint Neuro is being referred to more favorably in the media.

Company	Overall Sentiment
ClearPoint Neuro	Positive
Pro-Dex	Neutral

30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 6.9% of ClearPoint Neuro shares are held by insiders. Comparatively, 45.9% of Pro-Dex shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ClearPoint Neuro has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

ClearPoint Neuro presently has a consensus price target of $23.00, suggesting a potential upside of 31.43%. Pro-Dex has a consensus price target of $70.00, suggesting a potential upside of 11.31%. Given ClearPoint Neuro's higher probable upside, equities analysts plainly believe ClearPoint Neuro is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Pro-Dex has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	14.20	-$25.54M	-$1.01	N/A
Pro-Dex	$66.59M	3.01	$8.98M	$3.62	17.37

Summary

Pro-Dex beats ClearPoint Neuro on 9 of the 14 factors compared between the two stocks.

Get Pro-Dex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PDEX vs. The Competition

Export

Metric	Pro-Dex	MED/DENTAL Industry	Medical Sector	NASDAQ Exchange
Market Cap	$198.08M	$16.50B	$7.12B	$12.61B
Dividend Yield	N/A	1.33%	2.68%	7.83%
P/E Ratio	17.37	19.15	27.19	24.56
Price / Sales	3.01	2.39	590.19	121.71
Price / Cash	19.78	14.23	49.34	60.04
Price / Book	5.60	3.37	10.90	6.39
Net Income	$8.98M	$534.24M	$3.57B	$331.44M
7 Day Performance	2.54%	0.39%	-0.25%	0.37%
1 Month Performance	-0.05%	2.41%	4.53%	0.54%
1 Year Performance	39.72%	2.52%	29.18%	21.93%

Pro-Dex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PDEX Pro-Dex	2.351 of 5 stars	$62.89 +1.4%	$70.00 +11.3%	+31.7%	$198.08M	$66.59M	17.37	140	High Trading Volume
SGP Spyglass Pharma	2.179 of 5 stars	$22.26 +2.8%	$45.00 +102.2%	N/A	$744.22M	N/A	N/A	65
SSII SS Innovations International	2.4392 of 5 stars	$4.15 +17.6%	$7.00 +68.7%	-29.3%	$706.46M	$42.49M	N/A	4	Gap Up High Trading Volume
TCMD Tactile Systems Technology	3.6113 of 5 stars	$29.78 -1.6%	$38.60 +29.6%	+190.7%	$682.78M	$329.52M	33.84	1,086
BWAY Brainsway	2.4838 of 5 stars	$15.51 +2.2%	$16.00 +3.2%	+138.3%	$608.76M	$52.22M	44.32	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PDEX) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pro-Dex (PDEX) Competitors

PDEX vs. SGP, SSII, TCMD, BWAY, and CLPT

How does Pro-Dex compare to Spyglass Pharma?

Summary

How does Pro-Dex compare to SS Innovations International?

Summary

How does Pro-Dex compare to Tactile Systems Technology?

Summary

How does Pro-Dex compare to Brainsway?

Summary

How does Pro-Dex compare to ClearPoint Neuro?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDEX vs. The Competition

Pro-Dex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pro-Dex (PDEX) Competitors

PDEX vs. SGP, SSII, TCMD, BWAY, and CLPT

How does Pro-Dex compare to Spyglass Pharma?

Does the media prefer SGP or PDEX?

Which has preferable earnings & valuation, SGP or PDEX?

Do institutionals and insiders believe in SGP or PDEX?

Is SGP or PDEX more profitable?

Do analysts recommend SGP or PDEX?

Summary

How does Pro-Dex compare to SS Innovations International?

Is PDEX or SSII more profitable?

Which has preferable earnings and valuation, PDEX or SSII?

Which has more volatility & risk, PDEX or SSII?

Do analysts recommend PDEX or SSII?

Does the media prefer PDEX or SSII?

Do institutionals & insiders have more ownership in PDEX or SSII?

Summary

How does Pro-Dex compare to Tactile Systems Technology?

Do analysts prefer TCMD or PDEX?

Does the media favor TCMD or PDEX?

Do insiders & institutionals have more ownership in TCMD or PDEX?

Which has higher valuation & earnings, TCMD or PDEX?

Which has more risk and volatility, TCMD or PDEX?

Is TCMD or PDEX more profitable?

Summary

How does Pro-Dex compare to Brainsway?

Do analysts rate BWAY or PDEX?

Does the media favor BWAY or PDEX?

Which has preferable valuation & earnings, BWAY or PDEX?

Which has more volatility & risk, BWAY or PDEX?

Is BWAY or PDEX more profitable?

Do institutionals and insiders hold more shares of BWAY or PDEX?

Summary

How does Pro-Dex compare to ClearPoint Neuro?

Is CLPT or PDEX more profitable?

Does the media favor CLPT or PDEX?

Do insiders and institutionals have more ownership in CLPT or PDEX?

Which has more volatility and risk, CLPT or PDEX?

Do analysts rate CLPT or PDEX?

Which has better valuation and earnings, CLPT or PDEX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDEX vs. The Competition

Pro-Dex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools